Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells
Targeting regulatory T cells (Treg) represents a therapeutic option to abrogate tumor-associated immune suppression. Here the authors show that pharmacological degradation of BCL-XL preferentially induces apoptosis of tumor-infiltrating Treg, promoting CD8 T cell activation and anti-tumor immune res...
Guardado en:
Autores principales: | Ryan Kolb, Umasankar De, Sajid Khan, Yuewan Luo, Myung-Chul Kim, Haijun Yu, Chaoyan Wu, Jiao Mo, Xin Zhang, Peiyi Zhang, Xuan Zhang, Nicholas Borcherding, Daniel Koppel, Yang-Xin Fu, Song Guo Zheng, Dorina Avram, Guangrong Zheng, Daohong Zhou, Weizhou Zhang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/11696984783a45a99be93e6ba397acf8 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity
por: Yonghan He, et al.
Publicado: (2020) -
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,
por: Dongwen Lv, et al.
Publicado: (2021) -
Proteolysis-targeting chimeras and their implications in breast cancer
por: Angeles C. Tecalco-Cruz, et al.
Publicado: (2021) -
Potential application of proteolysis targeting chimera (PROTAC) modification technology in natural products for their targeted protein degradation
por: Guliang Yang, et al.
Publicado: (2022) -
Destroyers-for-Bases Agreement, 1940
Publicado: (2017)